REG - Genedrive PLC - Director/PDMR Shareholding

GenedriveAnnouncement

05/02/2020 17:40

RNS Number : 1217C
Genedrive PLC
05 February 2020
 


 
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
 
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Lisa Miele, a Person Closely Associated with Gino Miele R&D Director and a PDMR, acquired 8,636 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at a price of 8.875p per today.
 
Following these purchases, Gino Miele's total beneficial interest is 66,979 Ordinary Shares, 0.2% of the issued share capital of the Company.
 
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
 



1.         


Details of the person discharging managerial responsibilities / person closely associated




a.         


Name


Lisa Miele
 
 




2.         


Reason for the notification




a.         


Position/status


PCA of Gino Miele R&D Director




a.         


Initial notification
/Amendment


Initial notification




3.  


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a.         


Name


genedrive plc




b.         


LEI


213800ZYODIRZ87Y4K14




4.         


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a.         


Description of the
Financial instrument, type
of instrument
Identification code


Ordinary shares of 1.5 pence each
 
 
 
GB00B1VKB244




b.         


Nature of the transaction


Purchase




c.         


Price(s) and volume(s)


 



Price(s)


Volume(s)




8.875p


8,636



 




d.         


Aggregated information
·      Aggregated volume
·      Price
 


 
N/A
 




e.         


Date of the transaction


2020-02-05




f.         


Place of the transaction


London Stock Exchange, AIM



For further details please contact:



genedrive plc


+44 (0)161 989 0245




David Budd: CEO / Matthew Fowler: CFO


















Peel Hunt LLP (Nominated Adviser and Joint Broker)


+44 (0)20 7418 8900




James Steel / Oliver Jackson


















Stanford Capital Partners Limited (Joint Broker)


+44 (0)20 3815 8880




Patrick Claridge / John Howes


















Walbrook PR Ltd (Media Relations & Investor Relations)


+44 (0)20 7933 8780 or genedrive@walbrookpr.com




Paul McManus / Anna Dunphy


+44 (0)7980 541 893 / +44 (0)7876 741 001



 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAXASEDDEEFA